277 related articles for article (PubMed ID: 16332722)
1. Signalling cell cycle arrest and cell death through the MMR System.
O'Brien V; Brown R
Carcinogenesis; 2006 Apr; 27(4):682-92. PubMed ID: 16332722
[TBL] [Abstract][Full Text] [Related]
2. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells.
Yan T; Berry SE; Desai AB; Kinsella TJ
Clin Cancer Res; 2003 Jun; 9(6):2327-34. PubMed ID: 12796402
[TBL] [Abstract][Full Text] [Related]
3. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
4. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation.
Davis TW; Wilson-Van Patten C; Meyers M; Kunugi KA; Cuthill S; Reznikoff C; Garces C; Boland CR; Kinsella TJ; Fishel R; Boothman DA
Cancer Res; 1998 Feb; 58(4):767-78. PubMed ID: 9485033
[TBL] [Abstract][Full Text] [Related]
5. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
Moreland NJ; Illand M; Kim YT; Paul J; Brown R
Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
[TBL] [Abstract][Full Text] [Related]
6. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.
Yan T; Schupp JE; Hwang HS; Wagner MW; Berry SE; Strickfaden S; Veigl ML; Sedwick WD; Boothman DA; Kinsella TJ
Cancer Res; 2001 Nov; 61(22):8290-7. PubMed ID: 11719462
[TBL] [Abstract][Full Text] [Related]
7. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
[TBL] [Abstract][Full Text] [Related]
8. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
9. Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line.
Chauhan DP; Yang Q; Carethers JM; Marra G; Chang CL; Chamberlain SM; Boland CR
Clin Cancer Res; 2000 Oct; 6(10):3827-31. PubMed ID: 11051225
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair-dependent transcriptome changes in human cells treated with the methylating agent N-methyl-n'-nitro-N-nitrosoguanidine.
di Pietro M; Marra G; Cejka P; Stojic L; Menigatti M; Cattaruzza MS; Jiricny J
Cancer Res; 2003 Dec; 63(23):8158-66. PubMed ID: 14678970
[TBL] [Abstract][Full Text] [Related]
11. Defects of DNA mismatch repair in human prostate cancer.
Chen Y; Wang J; Fraig MM; Metcalf J; Turner WR; Bissada NK; Watson DK; Schweinfest CW
Cancer Res; 2001 May; 61(10):4112-21. PubMed ID: 11358834
[TBL] [Abstract][Full Text] [Related]
12. Mismatch repair proteins are activators of toxic responses to chromium-DNA damage.
Peterson-Roth E; Reynolds M; Quievryn G; Zhitkovich A
Mol Cell Biol; 2005 May; 25(9):3596-607. PubMed ID: 15831465
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair, G(2)/M cell cycle arrest and lethality after DNA damage.
Aquilina G; Crescenzi M; Bignami M
Carcinogenesis; 1999 Dec; 20(12):2317-26. PubMed ID: 10590226
[TBL] [Abstract][Full Text] [Related]
14. Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair.
Mohd AB; Palama B; Nelson SE; Tomer G; Nguyen M; Huo X; Buermeyer AB
DNA Repair (Amst); 2006 Mar; 5(3):347-61. PubMed ID: 16338176
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage.
Yamane K; Schupp JE; Kinsella TJ
Cancer Res; 2007 Jul; 67(13):6286-92. PubMed ID: 17616687
[TBL] [Abstract][Full Text] [Related]
16. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
17. Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX.
Mac Partlin M; Homer E; Robinson H; McCormick CJ; Crouch DH; Durant ST; Matheson EC; Hall AG; Gillespie DA; Brown R
Oncogene; 2003 Feb; 22(6):819-25. PubMed ID: 12584560
[TBL] [Abstract][Full Text] [Related]
18. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity.
Cortellino S; Turner D; Masciullo V; Schepis F; Albino D; Daniel R; Skalka AM; Meropol NJ; Alberti C; Larue L; Bellacosa A
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15071-6. PubMed ID: 14614141
[TBL] [Abstract][Full Text] [Related]
19. The mismatch repair system is required for S-phase checkpoint activation.
Brown KD; Rathi A; Kamath R; Beardsley DI; Zhan Q; Mannino JL; Baskaran R
Nat Genet; 2003 Jan; 33(1):80-4. PubMed ID: 12447371
[TBL] [Abstract][Full Text] [Related]
20. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
